This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Best Biotech CEO of 2010 Is...

BOSTON ( TheStreet) -- The Best Biotech CEO of 2010 is Mitch Gold of Dendreon (DNDN).

TheStreet's biotech readers have spoken and Gold, who led Dendreon through a topsy-turvy FDA approval process for the prostate cancer therapy Provenge, garnered a commanding 52% of the votes in the Best Biotech CEO of the Year poll.

Congratulations, Mitch!

Runner-up was Leonard Bell of Alexion Pharmaceuticals (ALXN - Get Report), with 39% of the vote. Third place went to Neurocrine Biosciences (NBIX) chief Kevin Gorman, with support from 9% of readers.

Six hundred forty-two votes were cast overall for the Best Biotech CEO nominees, a respectable turnout but far below the 2,100 votes cast for the companion Worst Biotech CEO poll. Is that because my Best CEO nominees weren't all that inspiring, or perhaps readers are more motivated to cast votes against executives they despise?

Nevertheless, Gold takes home the coveted Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. In many ways, Gold exemplifies the namesake of this award.

Swanson co-founded Genentech at a time when the company's scientists were figuring out how to genetically re-engineer animal cells to produce therapeutic proteins aka the first "biotech" drugs. At Dendreon, Gold and his team pioneered the development of the first FDA-approved personalized immunotherapy treatment for prostate cancer. Provenge may pave the way one day for a host of new drugs that harness the power of a patient's own immune system to fight cancer or other diseases.

TheStreet's past Best Biotech CEO winners were Human Genome Sciences' (HGSI) Thomas Watkins in 2009 and Myriad Genetics' (MYGN) Peter Meldrum in 2008.

All three CEO nominees -- Bell, Gorman and Gold -- were deserving of the award this year but they were not the only biotech execs worthy of praise in 2010. Questcor Pharmaceuticals (QCOR) CEO Don Bailey could have easily made the finalists list for the tremendous job selling Acthar Gel, which in turn, has made shareholders very happy. Celgene (CELG - Get Report) CEO Robert Hugin deserves kudos for commanding the last true growth stock in the large-cap biotech group.

Hats off to Orexigen Therapeutics (OREX - Get Report) CEO Michael Narachi for doing the impossible -- convincing an FDA advisory panel to vote positively on an obesity drug. It was a strong and overwhelmingly positive year clinically for Vertex Pharmaceuticals (VRTX - Get Report) and hepatitis C drug telaprevir, so congratulations to CEO Matt Emmens, who must share the adulation with former chief executive Joshua Boger.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
QCOR $93.60 1.65%
ALXN $141.11 0.00%
CELG $102.45 0.00%
NBIX $36.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs